Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging

[1] Han M(2003)Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 517-523

[2] Partin AW(2004)A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy Int J Radiat Oncol Biol Phys 59 380-385

[3] Zahurak M(2003)Advances in imaging in the postoperative patient with a rising prostate-specific antigen level Semin Oncol 30 616-634

[4] Piantadosi S(2004)The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy J Urol 172 133-136

[5] Epstein JI(1998)Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy J Urol 160 1387-1391

[6] Walsh PC(2007)Patterns of local failure following prostate brachytherapy J Urol 177 1759-63

[7] Chism DB(2007)Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2225-2229

[8] Hanlon AL(2006)Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8 43-48

[9] Horwitz EM(2006)[(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387-1398

[10] Feigenberg SJ(2007)18F-choline and/or BJU Int 99 1415-1420

[1] Han M(2003)Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 517-523

[2] Partin AW(2004)A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy Int J Radiat Oncol Biol Phys 59 380-385

[3] Zahurak M(2003)Advances in imaging in the postoperative patient with a rising prostate-specific antigen level Semin Oncol 30 616-634

[4] Piantadosi S(2004)The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy J Urol 172 133-136

[5] Epstein JI(1998)Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy J Urol 160 1387-1391

[6] Walsh PC(2007)Patterns of local failure following prostate brachytherapy J Urol 177 1759-63

[7] Chism DB(2007)Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2225-2229

[8] Hanlon AL(2006)Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8 43-48

[9] Horwitz EM(2006)[(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387-1398

[10] Feigenberg SJ(2007)18F-choline and/or BJU Int 99 1415-1420